Treatment of hepatitis C virus infection in the allograft

Liver Transplantation

Volumn 9, Issue 11, 2003, Pages

  Neuberger, James ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEPATITIS C ANTIBODY; PARACETAMOL; PEGINTERFERON ALPHA2B; POLYETHYLENE GLYCOL INTERFERON ALFA 2B; POLYETHYLENE GLYCOL-INTERFERON ALFA-2B; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ALLOTRANSPLANTATION; ANOREXIA; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CHILL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG COMBINATION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPEPSIA; ECONOMICS; EDEMA; ELECTROLYTE DISTURBANCE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GRAFT SURVIVAL; GROUPS BY AGE; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIA; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MALAISE; MENTAL DISEASE; MYALGIA; NAUSEA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; ORGAN DONOR; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RASH; RECURRENT DISEASE; RECURRENT VIRUS INFECTION; RETINA BLOOD VESSEL OCCLUSION; SEPSIS; SOMNOLENCE; TASTE DISORDER; THYROID DISEASE; VIRUS LOAD; VIRUS REPLICATION; VOMITING;

EID: 0242624513     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2003.50250     Document Type: Article

References (46)

1. Sanchez-Fueyo A, Restrepo JC, Quinto L, Bruguera M, Grande L, Sanchez-Taplas JM, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002;73:56-63.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
3. Willems B, Ede M, Marotta P, Greig P, Lilly L, Kneteman N, et al. Anti-HCV immunoglobulins for the prevention of graft infection in HCV-related liver transplantation [abstract]. J Hepatol 2002;36(suppl 1):S69A.
4. Sebagh M, Feray C, Falissard B, Yilmaz F, Rifai K, Bismuth H, et al. Ten and 5-year histological assessment of the liver allograft: Non-linear progression of fibrosis in HCV-related chronic hepatitis [abstract]. Hepatology 2002;36:181A.
5. Quadri R, Giostra E, Roskams T, Pawlotsky J, Mentha G, Rubia-Brandt L, et al. Immunological and virological effects of ribavirin in hepatitis C after liver transplantation. Transplantation 2002;73:373-378.
6. Cattral MS, Krajden M, Wanless IR, Rezig M, Cameron R, Greig PD, et al. A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplantation 1996;61:1483-1488.
7. Wright TL, Combs C, Kim M, Ferrel L, Bachetti P, Ascher N, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994;20:773-779.
8. Feray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, et al. An open trial of interferon alpha recombinant for hepatitis C after liver transplantation. Anti-viral effect sand risk of rejection. Hepatology 1995;22:1084-1089.
9. Wright H, Van Thiel D. Preliminary experience with alpha 2-b interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992;53:121-124.
10. Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JYN, Naomov NV, et al. A randomised study comparing ribavirin and interferon monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27:1403-1407.
11. Wright T, Combs C, Kim M, Ferrell L, Bachetti P, Ascher N, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994;20:773-779.
12. Cotler SJ, Taylor SL, Gretch DR, Bronner MP, Rizk R, Perkins JD, Carithers RL. Hyperbilirubinaemia and cholestatic liver injury in hepatitis-C infected liver transplant recipients. Am J Gastroenterol 2000;95:753-759.
13. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, et al. Pilot study of the combination of interferon alpha and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26:500-504.
14. Alberti A, Belli LS, Arnold A, de Carlis L, Rondinara G, Minola E, et al. Combined therapy with interferon and low-dose ribavirin in post-transplantation recurrent hepatitis C: A pragmatic study. Liver Transpl 2001;7:870-876.
15. Gopal DV, Rabk IJM, Berk BS, Corless CL, Chou S, Olyaei A, Orloff SL, Rosen HR. Treatment of progressive hepatitis recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001;7:181-190.
16. Bizollon T, Ducerf C, Trepo C. New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin. J Hepatol 1995;23(suppl 2):22-25.
17. Taltavull TC, Ramos E, Serrano T, Baliellas C, Canas C, Casanova A, et al. Long-term histological and virological follow-up of a selected group of liver transplanted (LT) patients with hepatitis C recidive who were treated with IFN alfa and ribavirin [abstract]. Hepatology 2002;36:181A.
18. Menon KV, Poterucha JJ, El-Amin OA, Burgart LJ, Kremers WK, Rosen C, et al. Treatment of post-transplant recurrence of hepatitis C infection with interferon and ribavirin-lessons on tolerability and efficacy. Liver Transpl 2002;8:623-630.
19. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: A non-randomised trial of interferon alpha alone versus interferon alpha and ribavirin. Liver Transpl 2001;7:863-869.
20. De Vera ME, Smallwood GA, Rosado K, Davis L, Martinez F, Sharma S, et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001;71:678-686.
21. Kornberg A, Hommann M, Tannapfel A, Wgner T, Grube T, Schotte U, et al. Long-term combination of interferon alpha-2b and ribavirin for hepatitis C recurrence in liver transplant patients. Am J Transplant 2001;1:350-355.
22. Firpi RJ, Abdelmalek MF, Soldesila-Pico C, Reed A, Hemming A, Howard R, et al. Combination of interferon alpha-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002;8:1000-1006.
23. Shakil AO, McGuire B, Crippen JS, Teperman L, Demetris AJ, Conjeevaram HS, et al. A pilot study of interferon alpha and ribavirin combination therapy in liver transplant recipients with recurrent hepatitis C. Hepatology 2002;36:1253-1258.
24. Lavezzo R, Franchello A, Smedile A, David E, Barbui A, Torrani M, et al. Treatment of recurrent hepatitis C in liver transplants: Efficacy of a six versus a twelve month course of interferon alfa-2b with ribavirin. J Hepatol 2002;37:247-252.
25. Mukherjee S, Gilroy McCashland TM, Schafer DF, Zetterman RK. Pegylated-interferon and ribavirin for recurrent hepatitis C after liver transplantation [abstract]. Hepatology 2002;36:184A.
26. Neff G, Lee YM, Slapak G, Safdar K, Morero R, Nery J, et al. Preliminary treatment results of liver transplant recipients with recurrent hepatitis C virus nonresponsive to interferon alpha-2band ribavirin using combination pegylated interferon alpha 2b with ribavirin. Hepatology 2002;36:183A [abstract]
27. Neff G, Montalbano M, Lee YM, Slapak G, Safdar K, Morrero R, et al. Naïve treatment results in liver transplant recipients with hepatitis C virus recurrence (HCV-R) using pegylated interferon alpha-2b combined with ribavirin: preliminary results [abstract]. Hepatology 2002;36:183A.
28. Levitsky J, Cohen SM, Dasgutpa KA, Faust TW, Te HS. Pegylated interferon therapy with/without ribavirin in liver transplant recipients with recurrent hepatitis C infection [abstract]. Hepatology 2002;36:182A
29. Khatib MA, Arenas J, Carey E, Moss A, Mulligan D, Ortiz J, et al. Treatment with combination of PEG IFN alpha-2B and ribavirin suppresses viral replication in liver transplant recipients with recurrent HCV hepatitis [abstract]. Hepatology 2002;36: 182A.
30. Bahra M, Steinmuller T, Neumann U, Neuhaus R, Neuhaus P. Pegylated interferon alfa-2B in patients with hepatitis C reinfection after liver transplantation [abstract]. Liver Transpl 2001;7: C7.
31. Ferenci P, Peck-Radosavljevic M, Vogel W, Graziadei JW, Riely C, Voight MD, et al. 40kD peginterferon alpha-2a (pegasys) in post-liver transplant recipients with established recurrent hepatitis C: Preliminary results of a randomised multicenter trial [abstract]. Hepatology 2001;34:406A.
32. Manzarbeitia C, Teperman L, Chalsani N, Sheiner PA, Wiesner R, Marks IM, et al. 40kDA peginterferon alpha-2a (pegasys) as aprophylaxis against hepatitis C recurrence after liver transplantation (LT): Preliminary results of a randomised multicenter trial [abstract]. Hepatology 2001;34:406A.
33. Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, et al. The efficacy of prophylactic interferon alpha-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998;28:831-838.
34. Singh N, Gajowski T, Wannstedt CF, Shakil AO, Wagnere MM, Fung JJ, et al. Interferon alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomised, controlled trial. Transplantation 1998;65:82-86.
35. Mazzaferro V, Regalia E, Pulvirenti A, Tagger A, Andreola S, Pasquale M, et al. Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. Transplant Proc 1997;29:519-520.
36. Manzarbeitia C, Tepermann L, Chalasani N, Sheiner P, Wiesner R, Marks I, et al. 40kD peginterferon as prophylaxis against HCV recurrence after liver transplantation [abstract]. Hepatology 2001;34:406A.
37. Terrault N, Khalili M, Bollinger K, Roberts J, Ascher N. Limitations in the use of a prophylactic antiviral strategy in hepatitis C infected patients undergoing liver transplantation [abstract]. Hepatology 2002;36:177A.
38. Saab S, Ly D, Han SB, Lin K, Rojter S, Ghobrial RM, Busuttil R. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl 2002;5: 449-457.
39. Dousset B, Conti F, Houssain D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver transplant recipients. N Engl J Med 1994;330:1160-1161.
40. Gatof D, Trotter JF, Everson GT. Ductopenic rejection associated with clearance of hepatitis C virus on interferon therapy after liver transplantation [abstract]. Hepatology 2002; 36:291A.
41. Taga SA, Washington MK, Terrault N, Wright TL, Somberg KA, Ferrell LD. Cholestatic hepatitis C in liver allografts. Liver Transpl Surg 1998;4:304-310.
42. Ong JP, Younossi ZM, Gramlich T, Goodman Z, Mayes J, Sarbah S, Yen-Lieberman B. Interferon alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C. Transplantation 2001; 71:1486-1487.
43. Ghobrial RM. Re-transplantation for recurrent hepatitis C. Liver Transpl 2002;8(suppl 1);S38-S43.
44. Sheiner PA, Schluger LK, Emre S, Thung S, Lau JY, Guy SR, et al. Re-transplantation for recurrent hepatitis C. Liver Transpl Surg 1997;3:130-136.
45. Nery JR, Nelf G, Nery C, Montalbino M, Weppler D, Kato T, et al. Liver retransplantation in HCV-infected patients: An 8-year, single center experience [abstract]. Hepatology 2002;36:80A.
46. McHutchinson J, Patel K. Future of hepatitis C. Hepatology 2002;36:S245-S252.